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compounds, LY231617 (10 mM) and amflutizole (20 mM), reduced chemiluminescence by 98% (n=5, p=0.009) and 88% (n=5, p=0.03), respectively.
Conclusions-The similarity of the chemiluminescence responses of colonic biopsy specimens from acetic acid induced colitis and ulcerative colitis to a range of conventional antioxidants and standard treatments suggests that this model is a useful method for testing the antioxidant potential of new therapies for inflammatory bowel disease. The antioxidant actions of dimethyl sulphoxide, ascorbate, and the novel compounds, amflutizole and LY231617 in this model suggest that these agents merit further assessment in the treatment of inflammatory bowel disease.
(Gut 1996; 39: 407-415) Keywords : ulcerative colitis, antioxidant, acetic acid, aminosalicylates, free radicals, superoxide dismutase.
It is now well recognised that reactive oxygen species (ROS) such as superoxide (02%), the hydroxyl radical (OH), hydrogen peroxide (H202), hypochlorous acid (HOCl) and oxidant derivatives, such as N-chloramines (RNHCI), are produced in excess by the inflamed mucosa in inflammatory bowel disease (IBD) and may be pathogenic.`q The predominant sources of ROS in the inflamed mucosa are probably activated mucosal phagocytic leucocytes5 and episodes of ischaemia reperfusion6 (Fig 1) . Increased arachidonic acid metabolism7 may also lead to excess mucosal ROS production. The resulting oxidant stress may overwhelm the endogenous defences that regulate ROS production during normal metabolism, particularly if there are comparatively low tissue levels of endogenous antioxidants, as in the colonic mucosa.8 Consequent tissue injury by ROS9 results from their direct reaction with carbohydrates, lipids, proteins, and DNA, stimulation of phospholipase A2,'0 5-lipoxygenase,," and neutrophil chemotaxis1,2 and activation of transcription factors involved in cytokine release and cell growth, such as NFKB,l3 c-fos, c-myc and c-jun. '4 It has been suggested that the efficacy of current standard treatments is related to their antioxidant actions.4 5-ASA is a potent antioxidant and reduces mucosal ROS production by inflamed human colorectal biopsy tissue in vitro,' as well as mucosal lipid peroxidation in ulcerative colitis (UC) in vivo.'5 Hydrocortisone and other glucocorticoids do not directly scavenge ROS but their antiinflammatory effects include inhibition of neutrophil function. '6 Recent, albeit uncontrolled, trials have suggested that specific antioxidant treatment may be therapeutically effective in IBD. In corticosteroid resistant Crohn's disease (CD) a combination of superoxide dismutase and desferrioxamine was reportedly effective, while allopurinol has been used successfully in acute and chronic pouchitis. ' 8 Antioxidants have been used successfully in experimental models of intestinal inflammation. '9 20 Compounds with antioxidant activity should therefore be investigated as potential treatments for IBD. There are many compounds with known antioxidant activity and many new potential therapies whose ability to reduce ROS production by inflamed colon is unknown. It would therefore be useful to have a method for screening potential treatments for this action. Recent findings from this laboratory have shown that ROS production by rectal biopsy specimens from patients with UC and CD can be measured in vitro using a chemiluminescence technique, and that addition of conventional antioxidants reduces the measurable ROS.' Biopsy material from patients with active UC is, however, too limited for screening multiple compounds.
Acetic acid induced colitis in rats resembles UC in histology, eicosanoid production,2' and response to sulphasalazine.22 Inflamed colonic mucosa in acetic acid induced colitis is also known to produce excess ROS and antioxidants will reduce measurable ROS23: in these studies, however, mucosal scrapings rather than biopsy specimens were used and no comparison was made with human material, thus limiting the comparability with IBD.
This study used full thickness colonic biopsy specimens from acetic acid induced colitis and validated the screening technique by comparing results with previous studies using biopsy specimens from patients with active UC, in which the conventional antioxidants (sodium azide, taurine, dimethyl sulphoxide, N-acetylcysteine, ascorbate and the enzymes catalase and CuZn superoxide dismutase) and two standard therapies for IBD (5-aminosalicylate (5-ASA) and hydrocortisone), were evaluated.' 24 25 In addition, we studied the effects of potential new antioxidant approaches with human recombinant manganese superoxide dismutase (Rh-Mn superoxide dismutase) and two novel antioxidants, LY231617 and amflutizole, whose structures are shown in Figure 2 . 
Methods
Maximum score 20 released in the form of photons, which are detected by the photomultiplier tubes and photon detectors that comprise the scintillation counter.28 Lucigenin responds more specifically to superoxide than luminol29 and was therefore used to detect changes in chemiluminescence induced by superoxide dismutase. Luminol and lucigenin were used at the same concentration (300 ,uM) as used in previous studies using human biopsy specimens.'
Full thickness biopsy specimens were taken at random by cutting cross sectional strips (median (IQR) wet weight; 44 (31-78) To assess the variability of the chemiluminescence response of colonic biopsy specimens from acetic acid induced colitis, the coefficient of variation was calculated from the chemiluminescence response in luminol produced by two to six biopsy specimens from each of 22 rats. 31 Comparisons between animals are expressed as the median and interquartile range (IQR) of the coefficient of variation. A similar calculation for the response to lucigenin was made in two to six specimens from each of 10 animals.
The macroscopic appearances, the histological score, and the chemiluminescence response were compared using Spearman's rank correlation coefficient.
Effect of water soluble compounds For each compound at each concentration a pair of biopsy specimens from each of ¢5 rats was used to assess the percentage change in chemiluminescence. The chemiluminescence counts before and after addition of test compound are given as ti and t2, respectively, and for the specimen treated with control, cl and c2, respectively. To take account of small changes in control values during the assay, the change in chemiluminescence produced by the test compound on one biopsy specimen was adjusted by the change in chemiluminescence produced by the control solution with its pair. Accordingly, the percentage change in chemiluminescence response induced by the test compound (/A%t) is calculated as follows:
A%t=((t2XCl/C2)-tl ) X 100.
The results are expressed as median % (IQR). The difference in chemiluminescence response between biopsy specimens treated with test compounds and controls is calculated by comparing the percentage change in chemiluminescence induced by the test agent and control using the Wilcoxon signed rank test for paired variables. A p value of less than 0.05 (two tailed) was taken as significant.
To investigate the variability of the change in chemiluminescence response produced by vehicle alone, the coefficient of variation of the response to D-PBS (control for most of the compounds tested) was calculated for two to six biopsies from each of 10 animals and the median (IQR) expressed for the coefficient of variation of the luminol amplified chemiluminescence response to D-PBS in all i0.È ffect of water insoluble compounds Results are expressed as the mean percentage change in chemiluminescence for each group of biopsy specimens exposed to the test compound after correction of the initial count for the percentage change induced by acacia alone (control). No range is given because grouping the biopsy specimens together resulted in loss of animal identity. The chemiluminescence counts before and after exposure to the test compound were compared using the Mann-Whitney U test. A p value of less than 0.05 (two tailed) was taken as significant.
To investigate the variability of the chemiluminescence response induced by incubation of biopsy specimens in 10% acacia, the median coefficient of variation was calculated for eight groups of five biopsies from five rats incubated in 10% acacia alone that were used as controls in experiments assessing the effect of water insoluble compounds.
Results

VALIDATION OF THE ACETIC ACID INDUCED COLITIS MODEL
Chemiluminescence response in acetic acid induced colitis compared with controls We compared the chemiluminescence response of 71 colonic biopsy specimens from 23 rats with acetic acid induced colitis to eight noninflamed colonic biopsy specimens from four rats given intracolonic 0.9% saline and 22 biopsy specimens from 10 untreated control rats (Fig 3) . The median (IQR) for each of these groups was 17 449 (6498-38 880) photons/min/mg, 74 (0-154), and 0 (0-66) respectively. For lucigenin amplified chemiluminescence, 26 colonic biopsy specimens from 10 rats with acetic acid induced colitis were compared with eight specimens from four rats given 0.9% saline and to 10 specimens from seven untreated controls (Fig 3) . The median (IQR) for these groups was 819 (518-1471) photons/min/mg, 347 (157-759), and 143 (48-227), respectively. Biopsy specimens from acetic acid induced colitis produced significantly more luminol amplified chemiluminescence than specimens from saline treated and untreated controls and more lucigenin amplified chemiluminescence than untreated controls (p<0.001) (Fig 3) . There was no difference in the chemiluminescence response of colonic tissue from the two control groups.
Chemiluminescence related to the severity of inflammation To assess the relation between ROS production as detected by chemiluminescence As for UC specimens, 5-ASA produced a significant reduction in luminol amplified chemiluminescence response in acetic acid induced colitis biopsy specimens (maximum -88 (-89 to -70)% at 20 mM 5-ASA, p=003) with a limited dose response producing an estimated IC50 of 4 mM (Fig 7) . Hydrocortisone did not alter luminol amplified chemiluminescence in either acetic acid induced colitis or UC biopsy specimens24 (Fig 7) .
RESPONSE OF BIOPSY SPECIMENS FROM ACETIC ACID INDUCED COLITIS TO POTENTIAL NEW TREATMENTS FOR IBD
Rh-Mn superoxide dismutase had no demonstrable antioxidant activity in this system, altering the lucigenin amplified and luminol amplified chemiluminescence response, respectively by -9 (-17 to +3)% and +17 (+10 to +37)%, respectively. However, two novel water insoluble antioxidant compounds, LY231617 (10 mM) and amflutizole (20 mM), produced noticeable reductions in luminol amplified chemiluminescence after incubation of the specimens in suspensions of the compounds in 10% acacia (means, -98%, p=0.009 and -88%, p=0.028, respectively) (Fig 8) . 5-ASA (20 mM), which had previously been shown to reduce luminol amplified chemiluminescence in aqueous solution, reduced the chemiluminescence by a similar amount (mean, 83% p=0.002) when tested in acacia.
Discussion
These findings show that full thickness colonic biopsy specimens from rats with acetic acid induced colitis produce increased levels of ROS, as detected by amplified chemiluminescence, compared with control tissue. In addition, we have found that the level of ROS production detected by luminol amplified chemiluminescence correlates with the grade Catalase Taurine CuZn DMSO NAC (U/ml) (mM) superoxide (%) (mM) dismutase (U/ml) Figure 6 : The percentage change in chemiluminescence response of inflamed biopsy specimens from acetic acid induced colitis to conventional antioxidants compared with results using mucosal biopsy specimens from active UC (tdata redrawn from references' 24 25) . Chemiluminescence was measured before and after exposure to test compound and compared with a second biopsy specimen exposed to vehicle (n S5; *denotes p<O 05 drug compared with vehicle, Wilcoxon signed rank test). Luminol was used as the amplifierfor chemiluminescence for aUl compounds except CuZn superoxide dismutase, for which lucigenin was used. NAC=N-acetylcysteine. Azide (mM) 20 20 Ascorbate (mM) of mucosal inflammation, as assessed by the macroscopic and histological score. These findings confirm previous studies using mucosal scrapings from rat acetic acid induced colitis. 22 We have now shown that colonic biopsy specimens from the acetic acid induced colitis model respond to conventional antioxidants and standard treatments for IBD, 5-ASA, and hydrocortisone, in a similar fashion to mucosal specimens from patients with active UC.1 24 25 The estimated IC50 of 5-ASA in this model compares favourably with the intraluminal concentrations recorded after oral administration of aminosalicylates (5-10 mM) in UC. 32 Of the conventional antioxidants examined, the greatest inhibition occurred with azide, a potent inhibitor of myeloperoxidase,28 which also inhibits other haem proteins such as catalase and quenches singlet oxygen and the hydroxyl ion.34 Although the antioxidant action of azide could result from a cytotoxic effect, azide has been shown to reduce the luminol amplified chemiluminescence of stimulated neutrophils to a greater effect when added before the stimulus (100%) than after (20%),35 an effect that would not occur if the reduction in chemiluminescence was purely due to cytotoxicity.
Superoxide is produced by the activated neutrophil, partly as the result of NADPH activity,36 and as a result of episodes of ischaemia reperfusion, which may be important in the pathogenesis of IBD37 (Fig 1) . colitis,'9 suggesting that hydrogen peroxide and its metabolites may contribute to colonic inflammation. An antioxidant effect for catalase can be demonstrated in both acetic acid induced colitis and UC biopsy specimens,' further supporting the suggestion that ROS produced by neutrophils are important in IBD.
N-acetylcysteine replenishes intracellular stores of glutathione, is a weak scavenger of superoxide and hydroperoxide but reacts avidly with hypochlorous acid and the hydroxyl radical.45 However, N-acetylcysteine was ineffective in reducing ROS production by acetic acid induced colitis or UC biopsy specimens under the present experimental conditions. 24 The physiological level of ROS is regulated by both enzymatic systems and direct oxygen scavengers, such as ascorbate, which reacts rapidly with superoxide, the hydroxyl radical,46 and hypochlorous acid.47 Ascorbate levels are decreased in the plasma in IBD.48`In this investigation ascorbate produced similar reductions in chemiluminescence in acetic acid induced colitis and human UC biopsy specimens.24 However, ascorbate is readily oxidised to the potentially damaging ascorbate radical in the presence of iron,50 present in the bowel lumen in millimolar quantities.3 This reaction could limit the potential usefulness of ascorbate as a treatment in UC.
The predominant antioxidant action of DMSO in vitro is scavenging of the hydroxyl ion.5 As the hydroxyl ion is extremely reactive, the local concentration of any scavenger would probably have to be prohibitively high to compete with biological molecules in the vicinity of its production. This may explain evidence from in vivo studies in which oral 5% (0-64 M) DMSO failed to improve acetic acid induced colitis.22 Nevertheless, the antioxidant effects of DMSO obtained here, and in UC biopsy specimens,l suggest that evaluation of its potential efficacy when given in enema formulation in high concentration to patients with distal UC may be worthwhile.
The hypochlorite scavenger taurine had little effect on ROS production by UC biopsy specimens' and no effect in this model, possibly because the reaction product of hypochlorous acid and taurine, taurine-Nchloramine, is itself an oxidant. 29 The novel agent, LY23 1617, protects against cerebral ischaemia in an animal model in vivo and ameliorates hydrogen peroxide induced neuronal damage in vitro.5' The potent antioxidant activity shown here suggests that it should be further evaluated as treatment in UC, perhaps initially in an enema or suppository formulation to achieve the necessary intraluminal concentration (10 mM).
We studied another antioxidant, amflutizole, which is a non-competitive inhibitor of xanthine oxidase and has also shown efficacy in a model of neuronal ischaemia.52 Ischaemia reperfusion with increased superoxide generation through xanthine oxidase activation36 may have a pathogenic role in IBD. Multifocal vascular microinfarction is a feature of CD37 and microvascular thrombi have been detected in both UC and CD.`3 The competitive xanthine oxidase inhibitor, allopurinol, has been of reported benefit in pouchitis. '8 In the present studies amflutizole was at least as effective as 5-ASA in reducing the chemiluminescence response of biopsy specimens from acetic acid induced colitis. Xanthine oxidase inhibition with amflutizole should, therefore, be further explored as a therapeutic option in IBD; again initial studies using topical treatment in distal UC would be desirable.
In conclusion, this in vitro system using biopsy specimens taken from rats with acetic acid colitis provides a convenient method for the screening of the antioxidant potential of new treatments for IBD. Agents that reduce ROS production by inflamed human colorectal biopsy specimens, such as CuZn superoxide dismutase, catalase, and DMSO also ameliorate inflammation in acetic acid induced colitis. Previous workers have suggested that the ROS production in both UC' and acetic acid induced colitis'9 22 is largely mediated by neutrophils, and the results here with azide, catalase, and CuZn superoxide dismutase support this proposal. The additional evidence of an antioxidant effect with the xanthine oxidase inhibitor, amflutizole, and previous evidence that allopurinol reduces ROS production by inflamed colonic biopsy specimens from acetic acid induced colitis22
suggests that, at least in this animal model, ischaemia reperfusion may also contribute to mucosal oxidant stress.
The limited antioxidant effect of antioxidant enzymes in both acetic acid induced colitis and UC biopsy specimens' may be because of poor tissue penetration or inactivation by hypochlorous acid54 produced by activated neutrophils; these factors may restrict their therapeutic potential.
Of the agents assessed in this study, dimethyl sulphoxide, ascorbate, amflutizole, and LY23 1617 seem most suitable for further evaluation in IBD.
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